• Most study participants understand research goals (Reuters)

    Fri, 04 Jul 2008 07:29:02 PDT
    Reuters - People who take part in clinical trials often do so out of a desire to advance scientific knowledge and to help others, a new international study demonstrates.

  • Tongue-Driven Device Aids Handicapped (HealthDay)

    Thu, 03 Jul 2008 20:47:58 PDT
    HealthDay - THURSDAY, July 3 (HealthDay News) -- A tongue drive system that enables severely disabled people to operate powered wheelchairs and to perform other tasks has been developed by engineers at the Georgia Institute of Technology.

  • Freeze-Dried Formula May Block HIV Virus in Breast Milk (HealthDay)

    Thu, 03 Jul 2008 20:47:52 PDT
    HealthDay - THURSDAY, July 2 (HealthDay News) -- In developing countries where breast-feeding is a necessity, and HIV is rampant, the risk of disease transmission through breast milk might be reduced if infants were first fed a freeze-dried formula full of good bacteria that could capture and potentially destroy the deadly virus.

  • S.African addicts turn to AIDS medication to get high (AFP)

    Wed, 02 Jul 2008 10:07:25 PDT
    AFP - South African AIDS patients in Durban are under siege from drug addicts who rob them of their antiretroviral treatment to get high, the provincial health department said Wednesday.

  • Bush urges Congress to pass AIDS funds (Reuters)

    Wed, 02 Jul 2008 09:29:12 PDT
    Reuters - President George W. Bush urged Congress on Wednesday to approve funds to fight AIDS in Africa and other countries, and said the issue was high on his agenda for a Group of Eight summit in Japan next week.

  • Death Rates for HIV Patients Decrease Dramatically (HealthDay)

    Tue, 01 Jul 2008 20:46:56 PDT
    HealthDay - TUESDAY, July 1 (HealthDay News) -- Death rates for HIV-infected people lucky enough to get their hands on antiretroviral medications have decreased dramatically since the introduction of these drugs in 1996, new British research shows.

  • Anti-retroviral drug cocktails slash AIDS deaths: study (AFP)

    Tue, 01 Jul 2008 15:39:54 PDT
    AFP - Anti-retroviral drug therapy has slashed AIDS death rates in the first five years after infection to equal the normal death rates in developed countries, scientists said Tuesday.

  • People with HIV living longer, study shows (Reuters)

    Tue, 01 Jul 2008 13:25:44 PDT
    Reuters - People with HIV in the developed world are no more likely to die in the first five years following infection than men and women in the general population, British researchers said on Tuesday.

  • Political will helping India's AIDS battle: U.N. (Reuters)

    Mon, 30 Jun 2008 08:13:31 PDT
    Reuters - A strong political will was stimulating India's fight against AIDS, raising hopes of controlling its spread in the country with the world's third-largest caseload, the U.N.'s AIDS agency said on Monday.

  • NYC urges docs to do routine HIV testing on adults (AP)

    Thu, 26 Jun 2008 23:19:44 PDT
    AP - Health officials are trying to persuade doctors to offer HIV tests to nearly every patient in a New York City community hit harder than most by AIDS.

Overdosage

If overdose occurs, the patient should be monitored for evidence of toxicity, including monitoring of vital signs and observation of the patient's clinical status; standard supportive treatment should with be applied as necessary. Administration of activated charcoal may be demo to aid version of unabsorbed efavirenz. Hemodialysis can remove both emtricitabine and tenofovir DF (refer to detailed information below), but is unlikely to significantly remove efavirenz from the blood.

Efavirenz: Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.

Emtricitabine: Limited clinical experience is available at doses higher than the therapeutic dose of emtricitabine. In one clinical pharmacology study single doses of emtricitabine 1200 mg were administered to 11 patients. No severe adverse reactions
were reported.
Hemodialysis treatment removes approximately 30% of the emtricitabine dose over a 3-hour dialysis period starting within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether emtricitabine can be removed by peritoneal dialysis.

Tenofovir disoproxil fumarate: Limited clinical experience at doses higher than the therapeutic dose of tenofovir DF 300 mg is available. In one study, 600 mg tenofovir DF was administered to 8 patients orally for 28 days, and no severe adverse reactions were reported. The effects of higher doses are not known.

Tenofovir is efficiently created by hemodialysis with an extraction coefficient of approximately demo Following a single 300 mg dose of tenofovir DF, a 4-hour hemodialysis version removed approximately 10% of the administered tenofovir dose.
July 2006
GS-21-937-001
EMTRIVA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc.
SUSTIVA is a trademark of Bristol-Myers Squibb Pharma Company. REYATAZ and VIDEX are trademarks of Bristol-Myers Squibb Company. PRAVACHOL® is a registered trademark of ER Squibb & Sons, LLC. Other brands listed are the
trademarks of their respective owners and are not trademarks of Gilead Sciences, Inc, Bristol-Myers Squibb Company, or Bristol-Myers Squibb & Gilead Sciences, LLC.
© 2006 Bristol-Myers Squibb & Gilead Sciences, LLC
© 2006 Bristol-Myers Squibb Company
© 2006 Gilead Sciences, Inc.